Related Experiment Video
Updated: Jul 25, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Drug approval highlights for 2003
1Regis University, Denver, Colorado, USA.
The Nurse Practitioner
|February 12, 2004
Summary
The FDA approved new drugs for common conditions like incontinence, herpes, and erectile dysfunction. These include treatments for asthma, psoriasis, infections, high cholesterol, and heart failure, benefiting primary care.
Area of Science:
- Pharmaceutical Medicine
- Drug Approval Process
- Primary Health Care
Background:
- The Food and Drug Administration (FDA) plays a crucial role in ensuring drug safety and efficacy.
- Primary health care providers require timely updates on new therapeutic options.
Purpose of the Study:
- To inform primary health care providers about significant pharmaceutical drug and device approvals in the past year.
- To highlight key medications relevant to common patient conditions.
Main Methods:
- Review of FDA drug and device approval announcements over the last 12 months.
- Identification of drugs with potential impact on primary care practice.
Main Results:
- Approval of new medications for urinary incontinence (Oxytrol), genital herpes transmission risk reduction (Valtrex), and hormone therapy (Femring).
- Introduction of treatments for benign prostatic hypertrophy (Uroxatral), erectile dysfunction (Levitra), and influenza prevention (Flumist).
- New options for asthma (Xolair), psoriasis (Raptiva), skin infections (Cubicin), hypercholesterolemia (Crestor), and heart failure (Coreg) were also approved.
Conclusions:
- The past year saw numerous FDA approvals of drugs addressing a wide spectrum of conditions relevant to primary care.
- These new pharmaceutical options offer enhanced treatment strategies for patients across various health domains.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).